The Center for Medical Image Science and Visualization (CMIV) will participate in an European collaboration for artificial intelligence in digital pathology.
The project has received financing from the Innovative Medicines Initiative, a public-private partnership under the EU research and innovation programme, Horizon 2020, reports Linköping University.
CMIV has a leading role
In order to enable a rapid development of AI within pathology, the project aims to create the first European, ethically secure and GDPR-compliant platform in which not only large-scale data but also AI algorithms can be stored. The platform will connect networks of pathologists, researchers, AI developers, patients and industrial partners.
Participants from Östergötland are LiU, Region Östergötland and the Sectra company. LiU and CMIV will be responsible for the construction of infrastructure (both hardware and software) for the whole of Bigpicture. Region Östergötland is to collect for the database anonymised digital pathology images in the field of skin conditions. Uppsala University is another participant from Sweden, and some of the infrastructure will be located there.
“It’s a great vote of confidence that CMIV has been awarded a leading role in Bigpicture. This demonstrates our international standing in this research field,” says Joel Hedlund, technical director and head of CMIV’s role in the project.
EUR 70 million in funding
The project will run for six years and has received EUR 70 million, or around SEK 700 million. LiU is to receive EUR 2.2 million of these, corresponding to around SEK 22 million. The project will be conducted within the Innovative Medicines Initiative (IMI), in a consortium that includes leading European research centres, hospitals and large pharmaceuticals companies.
The project is financed by the Innovative Medicines Initiative 2 Joint Undertaking, which has received support from the EU research and innovation programme Horizon 2020 and the European Federation of Pharmaceutical Industries and Associations (EFPIA).